Guangzhou Baiyunshan Pharmaceutical Stock Total Debt
| GZPHFDelisted Stock | USD 2.88 0.00 0.00% |
Guangzhou Baiyunshan Pharmaceutical fundamentals help investors to digest information that contributes to Guangzhou Baiyunshan's financial success or failures. It also enables traders to predict the movement of Guangzhou Pink Sheet. The fundamental analysis module provides a way to measure Guangzhou Baiyunshan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Guangzhou Baiyunshan pink sheet.
Guangzhou |
Guangzhou Baiyunshan Pharmaceutical Company Total Debt Analysis
Guangzhou Baiyunshan's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Guangzhou Baiyunshan Total Debt | 752.81 M |
Most of Guangzhou Baiyunshan's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Guangzhou Baiyunshan Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Guangzhou Baiyunshan Pharmaceutical has a Total Debt of 752.81 M. This is 72.64% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The total debt for all United States stocks is 85.84% higher than that of the company.
Guangzhou Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Guangzhou Baiyunshan's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Guangzhou Baiyunshan could also be used in its relative valuation, which is a method of valuing Guangzhou Baiyunshan by comparing valuation metrics of similar companies.Guangzhou Baiyunshan is currently under evaluation in total debt category among its peers.
Guangzhou Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0356 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 5.65 B | |||
| Shares Outstanding | 219.9 M | |||
| Shares Owned By Institutions | 33.99 % | |||
| Price To Earning | 6.77 X | |||
| Price To Book | 0.78 X | |||
| Price To Sales | 0.11 X | |||
| Revenue | 69.01 B | |||
| Gross Profit | 13.19 B | |||
| EBITDA | 5.46 B | |||
| Net Income | 3.72 B | |||
| Cash And Equivalents | 21.72 B | |||
| Cash Per Share | 13.36 X | |||
| Total Debt | 752.81 M | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 1.65 X | |||
| Book Value Per Share | 19.33 X | |||
| Cash Flow From Operations | 5.67 B | |||
| Earnings Per Share | 0.35 X | |||
| Number Of Employees | 25.44 K | |||
| Beta | 0.7 | |||
| Market Capitalization | 6.95 B | |||
| Total Asset | 66.12 B | |||
| Z Score | 6.4 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 66.12 B | |||
| Last Dividend Paid | 0.69 |
About Guangzhou Baiyunshan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Guangzhou Baiyunshan Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Guangzhou Baiyunshan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Guangzhou Baiyunshan Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Guangzhou Pink Sheet
If you are still planning to invest in Guangzhou Baiyunshan check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Guangzhou Baiyunshan's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |